User login
Key clinical point: Patients with migraine have an increased risk for comorbidities, and the risk is influenced by headache pain intensity and monthly headache days.
Major finding: Patients with migraine vs those without had an increased risk for insomnia, depression, anxiety, gastric ulcers/gastrointestinal bleeding, peripheral artery disease, angina, epilepsy, asthma, arthritis, stroke or transient ischemic attack, rheumatoid arthritis, allergies/hay fever, and vitamin D deficiency (P less than. 001). Increasing headache pain intensity was associated with an increased risk for inflammatory comorbidities, and monthly headache day frequency with risk for nearly all conditions.
Study details: The data come from the Migraine in America Symptoms and Treatment Study, which included 15,133 patients with migraine and 77,453 control individuals without migraine.
Disclosures: This study was funded and sponsored by Dr. Reddy’s Laboratories group of companies, Princeton, NJ. Sagar Munjal and Preeti Singh are employees of Dr. Reddy’s Laboratories. Richard B. Lipton, Dawn C. Buse, Michael L. Reed, Todd J. Schwedt, and David W. Dodick reported paid consultancy for Dr. Reddy’s Laboratories. The authors also reported ties with one or more pharmaceutical companies.
Citation: Buse DC et al. J Headache Pain. 2020 Mar 2. doi: 10.1186/s10194-020-1084-y.
Key clinical point: Patients with migraine have an increased risk for comorbidities, and the risk is influenced by headache pain intensity and monthly headache days.
Major finding: Patients with migraine vs those without had an increased risk for insomnia, depression, anxiety, gastric ulcers/gastrointestinal bleeding, peripheral artery disease, angina, epilepsy, asthma, arthritis, stroke or transient ischemic attack, rheumatoid arthritis, allergies/hay fever, and vitamin D deficiency (P less than. 001). Increasing headache pain intensity was associated with an increased risk for inflammatory comorbidities, and monthly headache day frequency with risk for nearly all conditions.
Study details: The data come from the Migraine in America Symptoms and Treatment Study, which included 15,133 patients with migraine and 77,453 control individuals without migraine.
Disclosures: This study was funded and sponsored by Dr. Reddy’s Laboratories group of companies, Princeton, NJ. Sagar Munjal and Preeti Singh are employees of Dr. Reddy’s Laboratories. Richard B. Lipton, Dawn C. Buse, Michael L. Reed, Todd J. Schwedt, and David W. Dodick reported paid consultancy for Dr. Reddy’s Laboratories. The authors also reported ties with one or more pharmaceutical companies.
Citation: Buse DC et al. J Headache Pain. 2020 Mar 2. doi: 10.1186/s10194-020-1084-y.
Key clinical point: Patients with migraine have an increased risk for comorbidities, and the risk is influenced by headache pain intensity and monthly headache days.
Major finding: Patients with migraine vs those without had an increased risk for insomnia, depression, anxiety, gastric ulcers/gastrointestinal bleeding, peripheral artery disease, angina, epilepsy, asthma, arthritis, stroke or transient ischemic attack, rheumatoid arthritis, allergies/hay fever, and vitamin D deficiency (P less than. 001). Increasing headache pain intensity was associated with an increased risk for inflammatory comorbidities, and monthly headache day frequency with risk for nearly all conditions.
Study details: The data come from the Migraine in America Symptoms and Treatment Study, which included 15,133 patients with migraine and 77,453 control individuals without migraine.
Disclosures: This study was funded and sponsored by Dr. Reddy’s Laboratories group of companies, Princeton, NJ. Sagar Munjal and Preeti Singh are employees of Dr. Reddy’s Laboratories. Richard B. Lipton, Dawn C. Buse, Michael L. Reed, Todd J. Schwedt, and David W. Dodick reported paid consultancy for Dr. Reddy’s Laboratories. The authors also reported ties with one or more pharmaceutical companies.
Citation: Buse DC et al. J Headache Pain. 2020 Mar 2. doi: 10.1186/s10194-020-1084-y.